McDade said this study has the longest-running data for any patients who started amyloid-lowering biologics while they were still free of symptoms. “We think that there’s a delay in the ...

But in just the past year and a half, two anti-amyloid drugs—lecanemab (Leqembi) and donanemab (Kisunla)—that can slow the progression of early Alzheimer’s disease have been approved in the US.

One such assembly, amyloid beta peptide, is synonymous with dementia, but researchers were not certain how these peptide assemblies "break bad" and what really causes them to assemble. Now ...

Gantenerumab helps eliminate one of the neurological hallmarks of Alzheimer’s, called amyloid plaques. For some participants, gantenerumab reduced their risk of developing the disease by more ...

The amyloid-β precursor protein (APP) helps to form links between the brain’s neurons. It has been highly studied because its breakdown creates amyloid-β peptides, which are often present in ...